ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Transient plasma p-tau217 elevations after electroconvulsive therapy: A two-case report.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPlasma phosphorylated tau (p-tau217) is increasingly used in the evaluation of Alzheimer's disease (AD). However, factors influencing its interpretation in real-world settings remain incompletely defined.
methodsWe describe a patient with repeated measurements of p-tau217 after an acute course of electroconvulsive therapy (ECT), complemented by a second patient with repeated measurements obtained during maintenance ECT.
resultsIn the primary case, p-tau217 was markedly elevated 3 weeks after completion of an acute ECT course (5.360 pg/mL; normal < 0.185 pg/mL), followed by a decline toward normal levels within weeks and normalization at follow-up. Cerebrospinal fluid biomarkers and neuropsychological assessment were normal. A second patient undergoing maintenance ECT demonstrated fluctuating levels of p-tau217. DISCUSSION: ECT may induce transient elevations of p-tau217 that could be misinterpreted as suggestive of AD pathology. The temporal profile suggests a reversible process distinct from amyloid-driven tau pathology. Deferring p-tau217 testing after ECT may reduce false-positive results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.